Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia I: Introduction01:29

Pneumonia I: Introduction

23
Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
23
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

1.4K
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
1.4K
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

4.6K
The pathophysiology of pneumonia involves the following steps:
4.6K
Pneumonia IV: Management01:28

Pneumonia IV: Management

1.2K
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.2K
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

1.7K
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
1.7K
Atypical Pneumonia01:14

Atypical Pneumonia

82
Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
82

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A pilot study of a sexual health workshop for oncology staff: feasibility, impact, and gaps in addressing young adult breast cancer survivorship needs.

Journal of cancer survivorship : research and practice·2026
Same author

[Emergency room visits for asthma and the reported outcomes: The PASS survey by the CRISALIS network].

Revue des maladies respiratoires·2025
Same author

[Durable Benefit from Immunotherapy in Advanced NSCLC: The BREATH Cohort].

Revue des maladies respiratoires·2025
Same author

Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Real-Life Management of Patients Aged 80 Years Old and Over With Multiple Myeloma: Results of the EMMY Cohort.

Clinical lymphoma, myeloma & leukemia·2024
Same author

Gynecologic cancer survivor preferences for provider communication regarding sexual health after treatment: a qualitative study.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2024
Same journal

[French version of the guidelines for connective tissue disease-associated ILD].

Revue des maladies respiratoires·2026
Same journal

[Pulmonary expression of an asymptomatic lysosomal storage disorder].

Revue des maladies respiratoires·2026
Same journal

[Factors associated with FEV1 evolution in cystic fibrosis patients treated by CFTR modulator tritherapy].

Revue des maladies respiratoires·2026
Same journal

[Subacute pulmonary coccidioidomycosis: A differential diagnosis of lung cancer].

Revue des maladies respiratoires·2026
Same journal

[Relevance of the ACT score in severe asthma with obesity: A pilot study].

Revue des maladies respiratoires·2026
Same journal

[Automated analysis of mandibular movements for the screening of obstructive sleep apnea].

Revue des maladies respiratoires·2026
See all related articles

Related Experiment Video

Updated: Apr 28, 2026

Methods for Detecting Cytotoxic Amyloids Following Infection of Pulmonary Endothelial Cells by Pseudomonas aeruginosa
07:27

Methods for Detecting Cytotoxic Amyloids Following Infection of Pulmonary Endothelial Cells by Pseudomonas aeruginosa

Published on: July 12, 2018

4.9K

[Hydroxyurea-induced pneumonia].

A Girard1, C Ricordel1, E Poullot2

  • 1Service de pneumologie, université de Rennes-1, CHU de Rennes, 2, rue Henri-Le-Guilloux, 35033 Rennes cedex 9, France.

Revue Des Maladies Respiratoires
|June 1, 2014
PubMed
Summary
This summary is machine-generated.

Hydroxyurea can cause lung inflammation (pneumonitis), a rare side effect. Early recognition and drug withdrawal are key for managing this hydroxyurea complication.

Keywords:
Drug-induced pneumonitisFeverFièvreHydroxyureaHydroxyuréeInterstitial lung diseasePneumopathie interstitiellePneumopathie médicamenteuse

More Related Videos

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

7.5K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

9.4K

Related Experiment Videos

Last Updated: Apr 28, 2026

Methods for Detecting Cytotoxic Amyloids Following Infection of Pulmonary Endothelial Cells by Pseudomonas aeruginosa
07:27

Methods for Detecting Cytotoxic Amyloids Following Infection of Pulmonary Endothelial Cells by Pseudomonas aeruginosa

Published on: July 12, 2018

4.9K
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

7.5K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

9.4K

Area of Science:

  • Pulmonology
  • Oncology
  • Pharmacology

Background:

  • Hydroxyurea is a vital antimetabolite medication for myeloproliferative disorders.
  • Common adverse effects include hematologic, GI, and cutaneous issues, alongside fever.
  • Hydroxyurea-induced pneumonitis is an uncommon but significant adverse event.

Observation:

  • A patient with polycythemia vera developed fever, cough, and nausea 20 days after starting hydroxyurea.
  • Chest CT revealed diffuse ground-glass opacities, with negative microbiological findings.
  • Symptoms resolved upon hydroxyurea discontinuation and recurred upon rechallenge.

Findings:

  • Hydroxyurea-induced pneumonitis presents with distinct acute febrile and subacute non-febrile patterns.
  • The acute form typically manifests within one month of initiating hydroxyurea therapy.
  • Review of 16 cases suggests these two presentations of drug-induced lung injury.

Implications:

  • Clinicians should consider hydroxyurea-induced pneumonitis in patients presenting with respiratory symptoms.
  • Prompt recognition and cessation of hydroxyurea are crucial for patient recovery.
  • Awareness of this rare complication is essential for safe hydroxyurea use in myeloproliferative neoplasms.